3rd Edition of Diabetes and Endocrinology World Conference 2027
Scientific Sessions - DEWC 2026
Incretin-based therapies play an essential role in the management of diabetes
Incretin-based therapies include GLP-1 receptor agonists and DPP-4 inhibitors, both of which play an essential role in enhancing meal-stimulated insulin secretion and inhibiting glucagon release, with the net effect of regulating blood glucose levels with additional benefits such as weight loss and improved cardiovascular health. GLP-1 receptor agonists delay gastric emptying, contributing to satiety and reduced appetite. New research has underlined the prospects these offer for maintaining beta-cell function and enhancing longer-term outcomes from type 2 diabetes. Incretin-based treatments form one of the corners of an individualized diabetes treatment model. The best platform, DEWC indeed, was where global experts engaged and explored recent developments in this class of incretin-based therapies.
Related Sessions
Welcome to the 3rd Edition of Diabetes and Endocrinology World Conference (DEWC) 2027
DEWC 2027 is a top- ...
Read More>>
Organizer
